GTB-5550 TriKE

Oct. 26, 2026: GT Biopharma, Inc. (NASDAQ: GTBP) announced it was selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, to be held November 4-8, 2026 in Phoenix, Arizona. The presentation, “Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy” (Abstract No. 655), is scheduled for November 6, 2026, from 3:05-3:20 PM MT in Session 106a on combination therapies involving cell therapy.

The presentation will be given by Paarth Dodhiawala of the University of Minnesota Medical School. The announcement indicates a conference data presentation catalyst focused on pancreatic cancer and NK cell immunotherapy, tied to GT Biopharma’s TriKE natural killer cell engager platform, but it does not disclose study results or clinical data.

The company also noted its exclusive worldwide license agreement with the University of Minnesota covering TriKE technology, including GTB-3650 and GTB-5550.